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Abstract
Ablative treatments such as photothermal therapy (PTT) are attractive anticancer strategies because they debulk accessible
tumor sites while simultaneously priming antitumor immune responses. However, the immune response following thermal
ablation is often insufficient to treat metastatic disease. Here we demonstrate that PTT induces the expression of
proinflammatory cytokines and chemokines and promotes the maturation of dendritic cells within tumor-draining lymph
nodes, thereby priming antitumor T cell responses. Unexpectedly, however, these immunomodulatory effects were not
beneficial to overall antitumor immunity. We found that PTT promoted the infiltration of secondary tumor sites by
CD11b+Ly-6G/C+ myeloid-derived suppressor cells, consequently failing to slow the growth of poorly immunogenic B16-F10
tumors and enhancing the growth of distant lung metastases. To exploit the beneficial effects of PTT activity against local
tumors and on antitumor immunity whilst avoiding the adverse consequences, we adoptively transferred gp100-specific
pmel T cells following PTT. The combination of local control by PTT and systemic antitumor immune reactivity provided by
adoptively transferred T cells prevented primary tumor recurrence post-ablation, inhibited tumor growth at distant sites,
and abrogated the outgrowth of lung metastases. Hence, the combination of PTT and systemic immunotherapy prevented
the adverse effects of PTT on metastatic tumor growth and optimized overall tumor control.
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Introduction
In situ tumor ablative strategies, including radiofrequency
ablation and cryoablation, are effective at destroying localized
disease and may stimulate the host immune system to recognize
and eliminate remaining tumor cells [1–4]. Tumor ablation
induces necrotic and apoptotic tumor cell death by direct
cytotoxicity and destruction of the tumor microvasculature [5].
Because dying tumor cells provide a source of tumor antigens and
induce the expression of natural immune adjuvants, like heat
shock proteins [6–9] and alarmins [10], they initiate an
inflammatory cascade that can promote dendritic cell maturation
[11,12] and culminate in the priming of tumor-specific T cells
[13–15]. It has been hoped that this immune response would then
have secondary beneficial effects on metastatic disease, progression
of which is the most common cause of cancer-related deaths.
Unfortunately, few local therapies have led to disease eradica-
tion by any immune response they putatively induce. We,
therefore, examined in greater detail the immune sequelae
induced in the wake of local tumor ablation using hyperthermia
with the goal of harnessing stimulatory immune components that
could be exploited for the eradication of metastatic disease. We
characterized the inflammatory and antitumor immune response
to B16-F10 melanoma induced by gold nanoshell-enabled
photothermal therapy (PTT), an ablation strategy that utilizes
optically tuned gold nanoshells that generate heat upon exposure
to near infrared radiation [16,17]. To evaluate the antitumor
effects initiated by PTT, we assessed the growth of distant tumor
metastases following primary tumor ablation and identified both
stimulatory and inhibitory immune components induced by PTT
that promote or suppress immune responses. To enhance systemic
antitumor effects, we determined if the immunostimulatory
environment induced by PTT could be exploited to promote the
expansion and function of adoptively transferred tumor-specific T
cells.
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We found that PTT promoted the expression of proinflamma-
tory cytokines and chemokines and induced the maturation of
dendritic cells (DC) within tumor-draining lymph nodes. These
effects did indeed lead to the priming of antitumor CD8+ effector
T cell responses. Unfortunately, this response also promoted the
generation of myeloid-derived suppressor cells and subsequently
enhanced metastatic tumor growth. The effects of PTT were,
however, sufficient to promote the expansion and function of
adoptively transferred tumor-specific T cells, such that the
combination of PTT and adoptive T cell therapy (ATCT), but
not either component alone, benefited both local and metastatic
disease. These data suggest that in situ tumor ablation and adoptive
immunotherapy can act in a complementary fashion and may be
of value for treatment of human cancer.
Materials and Methods
Mice
C57BL/6J, Albino C57BL/6J-Tyr-2J/J, and B6.Cg-Thy1a/Cy
Tg(TcraTcrb)8Rest/J [18] mice were purchased from Jackson
Figure 1. PTT stimulates the expression of proinflammatory cytokines and chemokines. Serum from B16-F10 tumor bearing mice was
isolated at 24 hours (n = 10 per group) and 96 hours (n = 8 per group) post-PTT and analyzed using a 32-plex cytokine/chemokine array. PTT induced
the expression of the pro-inflammatory cytokines (A) IL-6, TNF-a, IL-1b, and IL-12p70, cytokines that induce stem cell differentiation (B) GM-CSF, G-
CSF, M-CSF, and chemokines (C) CXCL-1, CCL-2 and CCL-4. Grey bars represent untreated tumor-bearing mice. Black bars represent PTT-treated mice.
Data are presented as the mean +/2 SEM. *p,0.05, **p,0.01, ***p,0.001; Student’s t-test.
doi:10.1371/journal.pone.0069073.g001
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Laboratories (Bar Harbor, ME) and maintained in a pathogen-free
mouse facility at Baylor College of Medicine according to
institutional guidelines. This study was carried out in strict
accordance with the recommendations of the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. This study was approved by the Institutional Animal Care
and Use Committees of Baylor College of Medicine. All
procedures were performed under anesthesia, and strong efforts
were made to minimize animal suffering.
Cell lines
The B16-F10 melanoma cell line (H-2kb) was obtained from the
American Type Culture Collection and used within 6 months of
receipt. ATCC utilizes COI for interspecies identification and
STR analysis for intraspecies identification. The B16-OVA cell
line was kindly provided by Dr. Xiao-Tong Song at Baylor College
of Medicine as previously described [19]. All cell lines were
screened and tested negative for Mycoplasma contamination by
PCR analysis. B16 melanoma tumor cells were cultured in
HyClone RPMI 1640 (Logan, UT) supplemented with 10% fetal
calf serum (FCS) and 2 mM glutamax (Invitrogen, Carlsbad, CA)
at 37uC and 5% CO2. B16-OVA media was supplemented with
0.5 mg/mL G418.
Mouse tumor model
B16-F10 and B16-OVA tumors were established on the lower
flanks of C57BL/6J mice by the subcutaneous injection of 56105
tumor cells. To establish lung metastases, 56105 B16-F10 tumor
cells were administered intravenously via tail vein infusion. The
length and width of tumors were measured 2–3 times per week by
digital caliper and volumes were calculated using the formula
(length26width60.5236) as previously described [20].
Gold nanoshell synthesis
Hollow gold nanoshells, tuned to the NIR, were synthesized via
a galvanic reaction in which gold tetrachloroauric acid (HAuCl4)
was reduced onto silver nanoparticles serving as sacrificial
templates. The process was adapted and modified from Prevo et
al. [21]. All chemicals were purchased from Sigma-Aldrich. In a
typical experiment, synthesis of hollow gold nanoshells were
prepared by first aging an aqueous solution of 0.2 mM silver
nitrate (AgNO3) in the presence of 0.5 mM sodium citrate. After
aging the solution, 50 mL aliquots were raised to ,60uC and a
1 mL injection of 100 mM sodium borohydride (NaBH4) solution
was added. The solution was allowed to stir for a minimum of
1 hour. After cooling to room temperature, additional AgNO3 was
added to grow the cores by first injecting 1 mL of 200 mM
hydroxy1amine hydrochloride (H3NO) to the solution followed by
an injection of 200 mL of 0.1 M AgNO3. After aging the solution,
hollow gold nanoshells were tuned to ,800 nm wavelength by
adding appropriate amounts of 1% HAuCl4 to the silver
nanoparticle solution and the silver cores were etched via galvanic
replacement. The resultant hollow gold nanoshells were quadruple
washed via centrifuge in distilled water. All reagents and
byproducts were removed from the solution.
Gold nanoshell-enabled photothermal therapy
Nanoparticles were sterilized by passing the solution through a
0.22 mm polyethylsulfone syringe filter. The day prior to PTT,
particles were coated with sterile polyethylene glycol (PEG-SH
=5 kDa) by adding an optimized amount of 1 mM PEG solution.
The optimized ratio of PEG molecules to gold nanoparticles was
determined using a salt stability assay. The nanoparticles and PEG
were incubated overnight at 4uC. Excess PEG molecules were
then removed by centrifuging the nanoparticles and removing the
Figure 2. PTT induces the maturation of DC within TDLN. B16-F10 tumor bearing mice were treated with PTT. 48 hours post-PTT, TDLN were
isolated and stained with antibodies to CD11c, CD80, CD86, CD40 and I-A/I-E and analyzed by flow cytometry. DC maturation was assessed by gating
on viable CD11c+ cells. Untreated tumor-bearing mice were used as controls (n = 3 per group). (A) Representative FACS plots of CD80, CD86, CD40
and I-A/I-E expression. (B) Corresponding mean fluorescent intensity (MFI) quantification of CD80 and I-A/I-E expression. Data represent the mean
+/2 SD. *p,0.05; Student’s t-test.
doi:10.1371/journal.pone.0069073.g002
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Figure 3. PTT induces systemic effects that influence T cell and MDSC tumor infiltration. B16-OVA tumors were established on opposing
flanks on days 0 and 7, respectively. Primary tumors were ablated by PTT on day 14. Mice were euthanized on day 23 for analysis of contralateral
tumors. The control group consisted of untreated tumor-bearing mice (Ctrl: n = 4, PTT: n = 5). (A) IFN-c ELISpot assay using CD8+ splenocytes
stimulated using LPS-matured DC pulsed with tumor-lysate. (B) Representative FACS plots and corresponding quantitative data demonstrating (C)
CD8+ and (D) CD4+ T cells infiltrating contralateral tumor sites. (E) Representative FACS plots and corresponding quantitative data demonstrating (F)
CD4+FoxP3+ Treg cells and (G) CD4+FoxP32 Thelper cells within contralateral tumor sites. (H) Teffector:Treg and (I) Thelper:Treg ratios within
Photothermal-Enhanced T Cell Therapy
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supernatant. The nanoparticles were then resuspended in sterile
16 PBS immediately prior to injection.
Tumors were treated with PTT once they reached a size of 5–
8 mm in diameter (day 10–14). The tumor region was first shaved,
then directly injected with 20 microliters of PEGylated hollow gold
nanoshells (40–42 nm outer diameter, shell thickness = 5–7 nm,
OD 40). Nanoshells were allowed to disperse throughout the
tumor for 5 minutes. The tumor was then swabbed with 100%
contralateral tumors. (J) Representative FACS plots and corresponding quantitative data measuring (K) CD11b+Ly-6G/C2 macrophages and (L)
CD11b+Ly-6G/C+ MDSC within contralateral tumor sites. Red line represents the mean. The data is representative of two or more experiments.
*p,0.05; z-test.
doi:10.1371/journal.pone.0069073.g003
Figure 4. PTT induces systemic MDSC expansion capable of suppressing T cell proliferation and function. B16-F10 tumors were
established on the flanks of C57BL/6J mice on day 0. Tumors were ablated by PTT on day 7. Mice were euthanized on day 12 for analysis. The control
group consisted of untreated tumor-bearing mice (Ctrl: n = 4, PTT: n = 5). (A) Representative FACS plots and (B) corresponding quantitative data
demonstrating CD11b+Ly6G/C+ cells within the spleens of control and PTT-treated mice. (C) Thymidine incorporation assay to measure T cell
proliferation 72 hours following CD3/CD28 stimulation of splenocytes at various ratios of splenocytes to Gr-1HighLy-6G+ cells (T cell: MDSC). (D) IFN-c
secretion to measure T cell function in response to CD3/CD28 stimulation at various ratios of splenocytes to Gr-1HighLy-6G+ cells (T cell: MDSC). The
data is representative of two or more experiments. *p,0.05, **p,0.01, ***p,0.001; ANOVA followed by Student’s t-test with multiple comparison
adjustment.
doi:10.1371/journal.pone.0069073.g004
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glycerol. A near-infrared laser (Coherent diode array laser, l=
808 nm, 3 W/cm2, spot diameter = 8 mm) irradiated the tumor
for 3 minutes.
Cytokine and chemokine multiplex
Serum was isolated from PTT-treated mice 24 hours and
96 hours post-ablation. As controls, serum was also obtained from
untreated, tumor-bearing mice. Serum cytokines and chemokines
were analyzed using a 32-plex murine cytokine/chemokine array
obtained from Millipore (Billerica, MA) as per the manufacturer’s
instructions.
Antibodies and flow cytometric analysis
Antibodies to CD4, CD8, CD40, CD80, CD86, I-A/I-E,
CD11c, CD11b, and Ly-6G/C were purchased from BD
Pharmingen (San Jose, CA). Intracellular FoxP3 staining was
performed using a Mouse Regulatory T Cell Staining Kit obtained
from eBioscience (San Diego, CA) as per the manufacturer’s
instructions. Stained cells were analyzed on a FACSCalibur
instrument (BD, Becton Dickinson, Mountain View, CA) and
analyzed using CellQuest software (BD).
In vivo DC maturation
Subcutaneous B16-F10 tumor cells were established on the
lower flanks of mice. Tumors were treated with PTT once they
Figure 5. PTT of a single tumor site can slow the growth of distant pre-established B16-OVA tumors but not less immunogenic B16-
F10 tumors. (A) B16-OVA or (B) B16-F10 tumor-bearing mice were treated with PTT then rechallenged with corresponding tumor cells 10 days post-
ablation. Naı¨ve mice were used as controls (n = 5 per group). Primary and secondary (C) B16-OVA or (D) B16-F10 were established on opposing flanks
on days 0 and 6, respectively. Primary tumors were ablated with PTT once they reached a size of 5–8 mm (day 12–14). Control mice did not receive
PTT (n = 5 per group). Data represent tumor growth over time and is displayed as mean +/2 SD. The data is representative of two or more
experiments. *p,0.05, **p,0.01; Student’s t-test.
doi:10.1371/journal.pone.0069073.g005
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reached a size of 5–8 mm in diameter. Forty-eight hours post-
PTT, mice were euthanized and tumor-draining (inguinal) lymph
nodes were harvested. Lymph nodes were homogenized through a
70 mm filter to create a single cell suspension then stained with
antibodies to CD11c, CD40 CD80, CD86, and I-A/I-E. DC
phenotype was assessed by flow cytometry after gating on viable
CD11c+ cells.
Analysis of contralateral tumor microenvironment
Contralateral tumors were isolated from mice 9 days following
PTT of primary day 14 established B16-OVA tumors. Tumors
were homogenized through a 70 mm filter to create a single cell
suspension. T cell subsets were stained using antibodies to CD4,
CD8, and FoxP3 and analyzed by flow cytometry after gating on
viable cells within the lymphocyte region. Myeloid-derived
suppressor cells were stained using antibodies to CD11b and Ly-
6G/C after gating on viable cells.
Isolation of myeloid-derived suppressor cells following
PTT
B16-F10 tumors were established on opposing flanks on day 0.
Primary tumors were ablated by PTT on day 7. The control group
consisted of untreated tumor-bearing mice. Mice were euthanized
on day 12 for analysis. Myeloid-derived suppressor cells (MDSC)
were isolated from the spleens of mice by magnetic separation of
Gr-1HighLy6G+ cells using a Myeloid-Derived Suppressor Cell
Isolation Kit purchased from Miltenyi Biotec (Cologne, Germany)
per manufacturer’s protocol.
Adoptive T cell transfer
Lymphocytes were isolated from the spleens of pmel mice by
density gradient separation using Lympholyte-M solution (CE-
DARLANE Laboratories, Burlington, NC). Lymphocytes were
maintained in Hyclone RPMI 1640 supplemented with 10% FCS,
2 mM glutamax, 10 mM HEPES, and 50 mM b-mercaptoethanol
at 37uC and 5% CO2. T cells were activated using 5 mg/mL
concanavalin A (Sigma, St. Louis, MO) and expanded using
10 ng/mL murine recombinant IL-2 (R&D Systems, Minneapolis,
MN) for 10–14 days. Twenty-four hours following PTT, pmel T
cells were washed, resuspended in PBS and infused intravenously
via tail vein (16107 cells/mouse).
Thymidine incorporation assay
Spleens were harvested from C57BL/6J mice and dissociated.
RBC lysis was performed on spleens using RBC lysis buffer (BD
Biosciences; Franklin Lakes, NJ). Splenocytes were seeded in
triplicate into 96-well round bottom plates at 16105 cells per well
in complete RPMI containing 10 ng/mL murine recombinant
IL-2 following CD3/CD28 activation of T cells using Mouse T-
Activator Dynabeads (Invitrogen). Cells were cultured in the
absence or presence of Gr-1HighLy6G+ cells at the following T
cell: MDSC ratios: 1:0, 1:1, 1:0.5 and 1:0.25. T cells were pulsed
with 5 mCi [3H] thymidine (Amersham Pharmacia Biotech,
Piscataway, NJ) 72 hours after stimulation for 18 hours. The cells
were then harvested onto glass filter strips and analyzed using a
TriCarb 2500 RT b-counter (Packard Biosciences, Downers
Grove, IL).
IFN-c ELISpot assay
The enzyme-linked immunospot (ELISpot) assay was per-
formed as previously described [22]. Spleens and/or tumor-
draining lymph nodes were harvested and dissociated. RBC lysis
was performed on spleens using RBC lysis buffer (BD
Biosciences; Franklin Lakes, NJ). T cells were activated for
24 hours and IFN-c secretion was detected using antibodies from
Mabtech (Nacka, Sweden). The number of spot forming cells
(SFCs) was quantified in a blinded manner (Zellnet Consulting,
New York, NY).
To detect immune priming post-PTT, CD8+ T cells were
purified from spleens by magnetic bead selection using CD8+ (Ly-
2) microbeads purchases from Miltenyi Biotec and syngeneic DC
were used as antigen presenting cells. Bone marrow-derived DC
were generated using IL-4 and GM-CSF as previously described
[23]. DC were pulsed with tumor lysate for 24 hours then matured
for an additional 24 hours using 50 ng/mL LPS (Sigma). 56105
CD8+ T cells were plated in triplicate in the presence of 26104
DC.
To measure the suppressive function of MDSC following PTT,
16105 splenocytes were plated in triplicate following CD3/CD28
activation of T cells using Mouse T-Activator Dynabeads
(Invitrogen). Cells were cultured in the absence or presence of
Gr-1HighLy6G+ cells at the following T cell: MDSC ratios: 1:0, 1:1,
1:0.5 and 1:0.25.
Figure 6. PTT promotes the expansion of adoptively transferred pmel T cells. Primary B16-F10 tumors were established on day 0, and
contralateral tumors were established on day 6. Primary tumors were ablated by PTT on day 10 followed by pmel ATCT on day 11. On day 20, mice
were euthanized and tissues were harvested for analysis. IFN-c secretion in response to hgp100 by cells isolated from the (A) spleen and (B) TDLN.
Treatment groups consisted of untreated tumor bearing mice (n = 5), PTT alone (n = 4), ATCT alone (n = 5), and dual PTT/ATCT (n = 5). The data is
representative of two or more experiments. *p,0.05, **p,0.01; ANOVA followed by Student’s t-test with multiple comparison adjustment.
doi:10.1371/journal.pone.0069073.g006
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To evaluate the pmel T cell response following ATCT, 16106
splenocytes or TDLN cells were plated in triplicate in the presence
of 10 mg/mL human hgp100 peptide (hgp10025–33:
KVPRNQDWL) obtained from Genemed Synthesis Inc. (San
Antonio, TX).
Statistical analysis
Student’s t-test was used to evaluate differences in the
expression of cytokines and chemokines, MFI values, tumor
growth in responses to treatment, as well as ELISpot data. For
comparisons of more than two groups, we performed Analysis of
Variance (ANOVA) followed by Student’s t-tests with multiple
comparison adjustment. Percentage differences in tumor infil-
trating cell types and tumor recurrence as well as fold changes in
bioluminescence were analyzed using a z-test for difference in
proportion. Significance was set a p,0.05. (*) represents p,0.05,
(**) represents p,0.01, and (***) represents p,0.001.
Results
PTT stimulates the expression of pro-inflammatory
cytokines and chemokines
To enable PTT, we synthesized 40 nm hollow GNS
(Figure S1) tuned to absorb NIR light at ,808 nm (Fig-
ure S2). To better understand the immune environment
established following PTT, we analyzed inflammatory cytokines
and chemokines present in the serum of PTT-treated mice
24 hours and 96 hours post-ablation. PTT induced the expres-
sion of the proinflammatory cytokines IL-6, TNF-a, IL-1b, and
IL-12p70 (Figure 1A). IL-6 was highly expressed at 24 hours
and normalized by 96 hours, whereas TNF-a remained elevated
for 96 hours. Both IL-1b and IL-12p70 were elevated at
96 hours. PTT also induced cytokines that stimulate stem cell
survival, growth, and differentiation (Figure 1B). Both GM-CSF
and M-CSF were significantly elevated 24 hours following PTT,
while G-CSF was expressed at significantly high levels for
Figure 7. ATCT prevents tumor recurrence post-PTT, while PTT enhances the antitumor efficacy of ATCT. Primary B16-F10 tumors were
established on day 0, and contralateral tumors were established on day 6. Primary tumors were ablated by PTT on day 10 followed by pmel ATCT on
day 11. (A) Primary tumor growth and (B) primary tumor recurrence in mice treated with PTT alone or dual PTT/ATCT (n = 23 per group). *p,0.05; Z-
test. (C) Growth of contralateral B16-F10 secondary tumors (n = 5 per group). Grey indicates tumor volume of individual mice. Red represents mean
tumor volume. The data is representative of two or more experiments. *p,0.05; Student’s t-test.
doi:10.1371/journal.pone.0069073.g007
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96 hours. In addition to cytokines, PTT induced the transient
expression of chemokines that direct the migration of immune
cells to sites of inflammation (Figure 1C). CXCL1, which serves
to attract neutrophils to the burn site, was significantly higher
24 hours post-PTT. CCL2 and CCL4, which attract monocytes,
macrophages and DC, were also significantly upregulated at the
same time point. Overall, PTT elicited a similar immune
response to that observed in burn patients, and the proin-
flammatory cytokine/chemokine profile is consistent with the
typical wound healing process [24,25].
PTT induces the maturation of DC within tumor-draining
lymph nodes
To determine if PTT results in the activation of DC subsets, we
engrafted mice with B16-F10 tumors, which were then subjected
to PTT. Forty-eight hours later, mice were euthanized and the
maturation status of DC within the spleen and tumor-draining
lymph nodes (TDLN) was assessed using flow cytometry by
costaining for CD11c and the maturation markers CD80, CD86,
I-A/I-E, and CD40. The maturation status of splenic DC
appeared unaffected by PTT (data not shown). However, DC
maturation could be detected in TDLN post-PTT (Figure 2).
These data suggest that PTT initiates a robust proinflammatory
process that leads to DC activation within the tumor microenvi-
ronment, an effect that could serve to prime antitumor immune
responses.
PTT induces systemic effects that influence T cell and
MDSC tumor infiltration
To determine if PTT leads to the priming of tumor-specific
effector T cells, CD8+ T cells were isolated from the spleens of
B16-OVA tumor bearing mice 7 days post-PTT. Their antigen
specificity was analyzed by an IFN-c ELISpot assay following
stimulation with tumor lysate-pulsed DC in treated and untreated
tumor-bearing mice. PTT-treated mice exhibited significantly
greater numbers of IFN-c secreting cells, indicating PTT induced
the priming of antitumor CD8+ effector T cell responses
(Figure 3A).
To analyze the effects of PTT on the immune response to distal
tumors, B16-OVA tumors were established on opposing flanks on
days 0 and 7, respectively. Primary tumors were ablated by PTT
on day 14, and mice were euthanized on day 23 for analysis of
contralateral tumors. Tumor infiltrating cells were analyzed by
flow cytometry following staining with antibodies to CD8, CD4,
and FoxP3. Compared to untreated tumor-bearing mice, PTT-
treated mice had significantly increased levels of infiltrating CD8+
Figure 8. ATCT abrogates the outgrowth of lung metastases induced by PTT. B16-F10 tumors were established on day 0. Contralateral
tumors were established s.c., and lung metastases were established by the administration of tumor cells i.v. on day 6. Primary tumors were ablated by
PTT on day 10 followed by pmel ATCT on day 11. On day 20, mice were euthanized and lungs were harvested for analysis. (A) Representative lung
photographs. (B) Lung mass and (C) quantification of lung metastases. Treatment groups consisted of untreated tumor bearing mice (n = 5), PTT
alone (n = 4), ATCT alone (n = 5), and dual PTT/ATCT (n = 5). *p,0.05; ANOVA followed by Student’s t-test with multiple comparison adjustment.
doi:10.1371/journal.pone.0069073.g008
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and CD4+ T cells in the contralateral tumor (Figure 3B–D). The
increase in CD4+ cell numbers was due to a rise in the proportion
of CD4+FoxP32 helper T cells in PTT-treated animals (Figure 3E
and G), and there was no equivalent rise in CD4+FoxP3+
regulatory T cells (Tregs) (Figure 3E and F). The net result of
PTT was an increase of both the Teffector:Treg and Thelper:Treg
ratios within the tumor microenvironment (Figure 3H and I),
which is significant because the efficacy of immunotherapeutic
regimens correlates with a shift in the intratumoral balance from
Tregs to Teffector cells [26].
Although Tregs were unchanged following PTT, we found a
substantial rise in the suppressive myeloid-derived suppressor cell
subset (MDSC) within the distal tumor microenvironment. While
PTT did not influence the number of CD11b+Ly-6G/C2
macrophages (Figure 3J and K) in contralateral tumors, the
levels of CD11b+Ly-6G/C + MDSC were greatly increased in
the distal tumor microenvironment (Figure 3J and L).
In summary, PTT primes effector and helper T cells that
infiltrate contralateral tumor sites. PTT does not increase Treg
infiltration of tumors, but promotes distal tumor accumulation of
MDSC. We did not detect any correlation between the degree of
CD4+, CD8+, and CD11b+Ly-6G/C+ cell infiltration following
PTT and tumor burden at the time of PTT or euthanasia, which
suggests these changes within the tumor microenvironment are a
result of PTT and not a direct effect of overall tumor burden.
PTT induces systemic MDSC expansion capable of
suppressing T cell proliferation and function
CD11b+Ly-6G/C+ cells comprise a heterogeneous population
of myeloid cells and granulocytes, and not all of these cells are
immunosuppressive. Therefore, we sought to determine whether
PTT induces systemic expansion of this particular cell population
and if these cells do in fact induce T cell dysfunction. We treated
B16-F10 tumor-bearing mice with PTT and isolated spleens 5
days after treatment. The control group consisted of untreated
tumor-bearing mice. Following PTT, we noted a significant
expansion of CD11b+Ly-6G/C+ cells within the spleens of mice in
comparison to untreated controls (Figure 4A and B). We next
evaluated the ability of these cells to induce T cell dysfunction. We
isolated Gr-1HighLy6G+ cells from the spleens of control and PTT-
treated mice and measured their effect on T cell expansion and
IFN-c secretion. Utilizing a thymidine incorporation assay, we
found that Gr-1HighLy6G+ cells isolated from both control and
PTT-treated mice significantly inhibit T cell proliferation follow-
ing CD3/CD28 stimulation at T cell: MDSC ratios of 1:1, 1:0.5
and 1:0.25 (Figure 4C). Interestingly, we found Gr-1HighLy6G+
cells isolated only from PTT-treated mice inhibited IFN- c
secretion following CD3/CD28 activation, whereas Gr-1High-
Ly6G+ cells isolated from control mice had no effect (Figure 4D).
These data suggest that PTT induces the systemic expansion of
Gr-1HighLy6G+ MDSC with enhanced suppressive activity in
comparison to untreated control mice.
PTT of a single tumor site can slow the growth of distant
pre-established B16-OVA tumors but not less
immunogenic B16-F10 tumors
Although PTT can treat localized tumors and induce the
immunomodulation described above, the combination of an
increased effector cell and an increased MDSC response calls
into question the overall potency of this antitumor immunity. We
first determined if PTT could prime an adaptive antitumor
immune response in a tumor rechallenge model targeting either
B16-OVA, a highly immunogenic tumor expressing the artificial
antigen ovalbumin, or the more weakly immunogenic B16-F10
tumor. These tumors were established on a single flank and then
treated with PTT once they reached 5–8 mm. Day 10 post-PTT,
mice were rechallenged on the contralateral flank with the
corresponding tumor cells and growth was monitored. We found
that PTT-treated mice could reject rechallenge with B16-OVA
(Figure 5A) and with the less immunogenic B16-F10 tumors
(Figure 5B).
We further tested the potency of the immune response by
determining whether the immune response established by PTT at
one tumor site could elicit antitumor activity at a pre-established
distant tumor site. We engrafted mice with primary B16-OVA or
B16-F10 tumors on a single flank. After 6 days, mice were injected
with the same tumor on the contralateral flank. When the primary
tumors reached 5–8 mm (day 12–14), they were treated with PTT
and the subsequent growth of both treated and contralateral
tumors was followed. PTT ablated the treated tumors derived
from B16-OVA and B16-F10 (Figure 5C and D). Growth of the
contralateral tumor was also inhibited in mice with B16-OVA
tumors (Figure 5C), but this distal immune effect did not occur in
mice implanted with the less immunogenic B16-F10 tumors
(Figure 5D).
PTT promotes the expansion of adoptively transferred
pmel T cells
Although PTT can prime adaptive antitumor immune
responses, the immune response induced by PTT could not
inhibit the growth of distant B16-F10 tumors. This data suggests
that to treat metastatic disease the immune response post-PTT
must be further modulated by applying combinational therapies
that work in concert with PTT. We reasoned that the antitumor
T-cell response induced by PTT was insufficient to overcome the
growth of tumors, likely because the beneficial effects of the pro-
inflammatory environment were countered by an associated rise
in MDSC levels, resulting in little benefit to the immunosup-
pressive tumor environment. We therefore measured the effects
of infusing tumor-directed activated T cells to exploit the T cell
promoting proinflammatory environment and avoid the con-
comitant inhibition of T cell activation associated with MDSC.
We first evaluated the potential stimulatory effects of PTT on
adoptively transferred pmel T cells, specific for the melanoma
tumor antigen gp100, by measuring the expansion and function of
pmel T cells infused post-ablation of B16-F10 tumors. Primary
and contralateral B16-F10 tumors were established on days 0 and
6 as before. Primary tumors were ablated by PTT on day 10.
Twenty-four hours following ablation, pmel T cells were infused
i.v. We then performed an ELISpot assay to measure the
frequency of pmel T cells within spleens (Figure 6A) and
tumor-draining lymph nodes (TDLN) (Figure 6B) 9 days after
adoptive transfer (day 20) by measuring IFN-c release in response
to hgp100. IFN-c secretion was only detected in conditions
administered pmel T cells, and the highest number of tumor-
reactive pmel T cells in the spleen (ATCT: 417+/2167, PTT/
ATCT: 909+/2240) and TDLN (ATCT: 461+/2167, PTT/
ATCT: 761+/2114) were found in mice treated with dual PTT/
ATCT. These data suggest that PTT can promote pmel T cell
expansion.
ATCT prevents tumor recurrence post-PTT, while PTT
enhances the efficacy of ATCT
The immune environment established by PTT appeared
beneficial to the survival and function of adoptively transferred
tumor-specific T cells. Thus, we next wished to evaluate the
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antitumor efficacy of a dual treatment approach utilizing PTT and
ATCT. Although PTT can debulk large vascularized tumors,
residual tumor cells at the treatment margins may result in tumor
recurrence, and the presence of tumor-specific T cells in the
immediate aftermath of PTT may serve to destroy remaining cells.
To evaluate tumor recurrence, B16-F10 tumors were established
on contralateral flanks of mice as before. The primary tumors were
treated with PTT at 5–8 mm, and half the mice also received ex
vivo-expanded pmel T cells 24 hours later. In mice treated with
PTT alone, the treated tumors recurred in 8/23 (34.8%),
compared to only 3/23 (13.0%) in mice receiving dual PTT/
ATCT (Figure 7A and B).
The combination of PTT and ATCT had equally beneficial
effects on distant, untreated (contralateral) tumors. While PTT or
ATCT alone were unable to inhibit the growth of pre-established
B16-F10 tumors (Figure 5D and 7C), dual PTT/ATCT
resulted in significant inhibition of contralateral tumor growth
(Figure 7C). These data suggest a complimentary relationship
exists between PTT and ATCT. ATCT can help to prevent
primary tumor recurrence after PTT, while the stimulatory
effects of PTT are necessary to enhance the antitumor activity of
adoptively transferred T cells for the effective treatment of distant
tumor sites.
PTT alone promotes the growth of lung metastases, but
synergizes with ATCT to enhance antitumor effects
The limitations of the immune response induced by PTT are
strikingly illustrated by its effects on metastatic lung disease. B16-
F10 tumors were established on a single flank on day 0. On day 6,
tumor cells were also administered i.v. to establish lung metastases.
Primary tumors were treated with PTT on day 10, and ex vivo
expanded pmel T cells were infused 24 hours post-ablation as
before. On day 20, lungs were harvested for analysis (Figure 8A–
C). Surprisingly, PTT greatly accelerated the growth of metastatic
lung tumors in the absence of ATCT, while ATCT alone only
modestly decreased lung disease burden compared to controls.
However, ATCT in combination with PTT not only abrogated
the enhanced metastatic tumor growth induced by PTT, but it
resulted in significantly greater antitumor effects compared to
ATCT alone.
Discussion
This study highlights a dual therapeutic strategy utilizing PTT
and ATCT for the treatment of metastatic cancer. Although PTT
was capable of both treating local tumors and priming effector T
cell responses, the inflammatory environment induced by PTT
concomitantly initiated inhibitory immune mechanisms mediated
by MDSC, and the resulting antitumor immune response was
ineffective in eliminating distant tumors. However, we were able to
exploit the stimulatory immune environment and overcome
inhibitory immune components via the adoptive transfer of
tumor-targeted T cells. This approach led to the eradication of
both local and metastatic disease and provides a rationale for
combining local ‘‘in vivo vaccination’’ by PTT and adoptive
transfer of tumor-specific CTLs.
Despite clear evidence that ablative therapies can prime
antitumor T cell responses, and in some cases are associated with
spontaneous remission of secondary tumors [1,2], this response is
usually insufficient to eliminate metastatic disease. Such an
observation is not surprising given that other immunotherapeutic
strategies, such as cancer vaccines, often fail to elicit robust
antitumor effects [27] because tumors evolve mechanisms to avoid
immune detection and inhibit effector T cell function by
establishing a suppressive tumor microenvironment consisting of
Tregs and MDSC. We found that PTT monotherapy greatly
increased the frequency of MDSC systemically and within
contralateral tumors (Figure 3J–L, Figure 4B). We determined
that Gr-1HighLy6G+ MDSC isolated following PTT could more
potently induce T cell dysfunction (Figure 4D). This expansion
and activation of MDSC following PTT may serve to explain why
PTT monotherapy significantly worsened metastatic lung disease
(Figure 8). Additionally, the systemic cytokine profile established
in the wake of PTT could accelerate tumor cell growth by direct
stimulatory effects on tumor cells. PTT was found to dramatically
increase systemic levels of IL-6, which has been shown to promote
the growth of B16-F10 via the activation of STAT3 signaling [28].
Both TNF-a and IL-1b, also found to be upregulated following
PTT, can promote tumor growth by inducing IL-6 expression
[29]. Furthermore, inflammatory cytokines may promote angio-
genesis via increased secretion of VEGF and MMP9 [30].
Cytokines and chemokines released following PTT could also
accelerate metastatic tumor growth by promoting MDSC
generation. MDSC expansion and recruitment is observed in a
wide range of acute and chronic inflammatory processes, such as
cancer, burns, trauma, sepsis, and autoimmunity [31]. IL-1b
promotes the expansion of MDSC [32,33], and IL-6 acts as a
downstream mediator of this process [34]. Expansion of MDSC
during inflammatory processes is believed to result from
increased myelopoiesis in combination with premature arrest of
myeloid differentiation. Following PTT, we detected increased
systemic levels of G-CSF, M-CSF, and GM-CSF, all of which
are cytokines involved in promoting myelopoiesis. Furthermore,
G-CSF, M-CSF, and GM-CSF have been found to accelerate
tumor growth by promoting the expansion of MDSC [35–39].
Additionally, chemokines like CCL2 can recruit MDSC to tumor
sites [40].
To generate effective antitumor results, T cell responses must
be robust to overcome the suppressive tumor microenvironment.
To augment the immune effects following ablative therapies,
others have employed techniques to enhance the generation and
effector functions of tumor-specific T cells. Toll-like receptor
ligands [41,42] and homeostatic cytokines, like IL-7 and IL-15
[43], have been employed to promote the generation and
expansion of tumor-specific T cells. Alternatively, antibodies that
block inhibitory T cell receptors, like CTLA-4 [26], and
strategies that eliminate suppressive cell types within the tumor
microenvironment, like Tregs [44], improve T cell effector
functions. Although these strategies have improved the systemic
antitumor effects of thermal ablation, they rely solely on the
endogenous generation and expansion of tumor-specific T cells
within the tumor-bearing host, a setting with an abundance of
suppressive influences generated by the host immune system [45]
and tumor microenvironment [46].
ATCT is an immunotherapeutic approach whereby autologous
tumor-specific T cells are expanded to large numbers ex vivo then
administered to the patient. In the setting of metastatic melanoma,
ATCT can produce objective clinical responses in over 50% of
patients [47,48]. However, adoptively transferred T cells are still
subject to tumor immunosuppression and often fail to persist in
vivo, resulting in few lasting and durable responses [49]. Thus,
adoptively transferred T cells are poised to benefit from the
vaccine-like effect established by PTT. In the immediate aftermath
of tumor ablation, pro-inflammatory cytokines and chemokines
are expressed. Chemokines such as CCL2 and CCL4 could help
recruit transferred T cells to the primary tumor site and thereby
prevent tumor recurrence [50,51], and inflammatory cytokines
like IL-6 can promote effector T cell infiltration of distant tumor
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sites [52]. Furthermore, tumor-antigens are released, DC are
activated, and the suppressive tumor microenvironment is
destroyed. The culmination of these events could enhance the
efficacy of ATCT by promoting the activation and function of
transferred tumor-specific T cells. Such a combined treatment
modality may help to negate the need for potentially toxic methods
of T cell activation and expansion following adoptive transfer,
such as host lymphodepletion or systemic IL-2 therapy. Alterna-
tively, this therapy may further benefit from concurrent adjuvant
therapies such as the use of checkpoint inhibitors like CTLA-4
antibodies [26] or via chemotherapeutic targeting of MDSC [53].
We found that the immune environment created by PTT could
promote the expansion of adoptively transferred pmel T cells,
leading to increased frequencies of tumor-specific T cells within
the spleens and TDLN of mice (Figure 6). Furthermore, a
combined treatment approach of PTT and ATCT had greater
antitumor effects than either treatment alone. ATCT could
prevent tumor recurrence following PTT, and PTT was necessary
for pmel-mediated inhibition of distant tumor sites (Figure 7).
Although a single treatment of ATCT was capable of alleviating
the severity of metastatic lung disease, dual PTT/ATCT yielded
the greatest antitumor effects (Figure 8).
This study highlights the benefit of combining PTT and ATCT
for the treatment of metastatic disease and the ineffectiveness of
either therapy alone. Dual PTT/ATCT greatly reduced tumor
burden by eradicating primary tumors and promoting the
antitumor activity of adoptively transferred T cells at distant
tumor sites.
Supporting Information
Figure S1 HGN TEM image. TEM image of as-synthesized
HGNs. The inset shows the morphological profile of an individual
HGN.
(TIF)
Figure S2 UV-VIS-NIR. UV-VIS-NIR spectra for as-synthe-
sized HGNs tuned to ,808 nm. The UV-VIS-NIR spectrum was
obtained using a Cary 60 Spectrophotometer.
(TIF)
Acknowledgments
We would like to thank Dr. Malcolm K. Brenner, Dr. Cliona M. Rooney,
and Dr. Stephen M. Gottschalk for their generous support and guidance.
We would also like to thank An Lu and Jessica Lunsford for their technical
support.
Author Contributions
Conceived and designed the experiments: ASB LCK JKY RAD AEF.
Performed the experiments: ASB LCK JKY SKP. Analyzed the data: ASB
LCK. Contributed reagents/materials/analysis tools: JKY JPMA AYL
PCE. Wrote the paper: ASB LCK JKY RAD AEF.
References
1. Soanes WA, Ablin RJ, Gonder MJ (1970) Remission of metastatic lesions
following cryosurgery in prostatic cancer: immunologic considerations. The
Journal of urology 104: 154–159. Available: http://www.ncbi.nlm.nih.gov/
pubmed/4987666. Accessed 3 April 2013.
2. Rao P, Escudier B, De Baere T (2011) Spontaneous regression of multiple
pulmonary metastases after radiofrequency ablation of a single metastasis.
Cardiovascular and interventional radiology 34: 424–430. Available: http://
www.ncbi.nlm.nih.gov/pubmed/20532778. Accessed 3 April 2013.
3. Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, et al. (2012) Phase 1
study of stereotactic body radiotherapy and interleukin-2– tumor and
immunological responses. Science translational medicine 4: 137ra74. Available:
http://www.ncbi.nlm.nih.gov/pubmed/22674552. Accessed 3 April 2013.
4. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, et al. (2012) In
situ vaccination against mycosis fungoides by intratumoral injection of a TLR9
agonist combined with radiation: a phase 1/2 study. Blood 119: 355–363.
Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3257006
&tool=pmcentrez&rendertype=abstract. Accessed 22 March 2013.
5. Widenmeyer M, Shebzukhov Y, Haen SP, Schmidt D, Clasen S, et al. (2011)
Analysis of tumor antigen-specific T cells and antibodies in cancer patients
treated with radiofrequency ablation. International journal of cancer Journal
international du cancer 128: 2653–2662. Available: http://www.ncbi.nlm.nih.
gov/pubmed/20715115. Accessed 3 April 2013.
6. Huang XF, Ren W, Rollins L, Pittman P, Shah M, et al. (2003) A broadly
applicable, personalized heat shock protein-mediated oncolytic tumor vaccine.
Cancer research 63: 7321–7329. Available: http://www.ncbi.nlm.nih.gov/
pubmed/14612530. Accessed 3 April 2013.
7. Yang W-L, Nair DG, Makizumi R, Gallos G, Ye X, et al. (2004) Heat shock
protein 70 is induced in mouse human colon tumor xenografts after sublethal
radiofrequency ablation. Annals of surgical oncology 11: 399–406. Available:
http://www.ncbi.nlm.nih.gov/pubmed/15070600. Accessed 3 April 2013.
8. Rai R, Richardson C, Flecknell P, Robertson H, Burt A, et al. (2005) Study of
apoptosis and heat shock protein (HSP) expression in hepatocytes following
radiofrequency ablation (RFA). The Journal of surgical research 129: 147–151.
Available: http://www.ncbi.nlm.nih.gov/pubmed/15975593. Accessed 3 April
2013.
9. Liu Q, Zhai B, Yang W, Yu L-X, Dong W, et al. (2009) Abrogation of local
cancer recurrence after radiofrequency ablation by dendritic cell-based
hyperthermic tumor vaccine. Molecular therapy: the journal of the American
Society of Gene Therapy 17: 2049–2057. Available: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid = 2814395&tool = pmcentrez&
rendertype = abstract. Accessed 3 April 2013.
10. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, et al. (2007) High mobility
group box-1 protein induces the migration and activation of human dendritic
cells and acts as an alarmin. Journal of leukocyte biology 81: 59–66. Available:
http://www.ncbi.nlm.nih.gov/pubmed/16966386. Accessed 3 April 2013.
11. Gallucci S, Lolkema M, Matzinger P (1999) Natural adjuvants: endogenous
activators of dendritic cells. Nature medicine 5: 1249–1255. Available: http://
www.ncbi.nlm.nih.gov/pubmed/10545990. Accessed 3 April 2013.
12. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, et al. (2009)
Immunogenic cell death modalities and their impact on cancer treatment.
Apoptosis: an international journal on programmed cell death 14: 364–375.
Available: http://www.ncbi.nlm.nih.gov/pubmed/19145485. Accessed 14
March 2013.
13. Shi Y, Zheng W, Rock KL (2000) Cell injury releases endogenous adjuvants that
stimulate cytotoxic T cell responses. Proceedings of the National Academy of
Sciences of the United States of America 97: 14590–14595. Available: http://
www.pubmedcentral.nih.gov/articlerender.fcgi?artid = 18963&tool = pmcentrez
&rendertype= abstract. Accessed 3 April 2013.
14. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, et al. (2000)
Consequences of cell death: exposure to necrotic tumor cells, but not primary
tissue cells or apoptotic cells, induces the maturation of immunostimulatory
dendritic cells. The Journal of experimental medicine 191: 423–434. Available:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid = 2195816&tool =
pmcentrez&rendertype = abstract. Accessed 3 April 2013.
15. Castano AP, Mroz P, Hamblin MR (2006) Photodynamic therapy and anti-
tumour immunity. Nature reviews Cancer 6: 535–545. Available: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid = 2933780&tool = pmcentrez&
rendertype = abstract. Accessed 3 April 2013.
16. Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, et al. (2003)
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic
resonance guidance. Proceedings of the National Academy of Sciences of the
United States of America 100: 13549–13554. Available: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid = 263851&tool = pmcentrez&
rendertype = abstract. Accessed 3 April 2013.
17. O’Neal DP, Hirsch LR, Halas NJ, Payne JD, West JL (2004) Photo-thermal
tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer
letters 209: 171–176. Available: http://www.ncbi.nlm.nih.gov/pubmed/
15159019. Accessed 14 March 2013.
18. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, et al. (1998)
gp100/pmel 17 is a murine tumor rejection antigen: induction of ‘‘self’’-reactive,
tumoricidal T cells using high-affinity, altered peptide ligand. The Journal of
experimental medicine 188: 277–286. Available: http://www.pubmedcentral.
nih.gov/articlerender.fcgi?artid = 2212458&tool = pmcentrez&rendertype =
abstract. Accessed 3 April 2013.
19. Song X-T, Turnis ME, Zhou X, Zhu W, Hong B-X, et al. (2011) A Th1-
inducing adenoviral vaccine for boosting adoptively transferred T cells.
Molecular therapy: the journal of the American Society of Gene Therapy 19:
211–217. Available: http://www.pubmedcentral.nih.gov/articlerender.
fcgi?artid = 3017450&tool = pmcentrez&rendertype = abstract. Accessed 3 April
2013.
Photothermal-Enhanced T Cell Therapy
PLOS ONE | www.plosone.org 12 July 2013 | Volume 8 | Issue 7 | e69073
20. Hanks BA, Jiang J, Singh RAK, Song W, Barry M, et al. (2005) Re-engineered
CD40 receptor enables potent pharmacological activation of dendritic-cell
cancer vaccines in vivo. Nature medicine 11: 130–137. Available: http://www.
ncbi.nlm.nih.gov/pubmed/15665830. Accessed 3 April 2013.
21. Prevo BG, Esakoff SA, Mikhailovsky A, Zasadzinski JA (2008) Scalable routes to
gold nanoshells with tunable sizes and response to near-infrared pulsed-laser
irradiation. Small (Weinheim an der Bergstrasse, Germany) 4: 1183–1195.
Ava i l ab l e : h t t p ://www.pubmedcen t ra l . n ih . gov/a r t i c l e r ende r .
fcgi?artid = 2692070&tool = pmcentrez&rendertype = abstract. Accessed 3 April
2013.
22. Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, et al. (2003)
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for
the adoptive immunotherapy of EBV-associated malignancies. Blood 101: 1905–
1912. Available: http://www.ncbi.nlm.nih.gov/pubmed/12411306. Accessed 3
April 2013.
23. Turnis ME, Song X-T, Bear A, Foster AE, Gottschalk S, et al. (2010) IRAK-M
removal counteracts dendritic cell vaccine deficits in migration and longevity.
The Journal of Immunology 185: 4223–4232. Available: http://www.ncbi.nlm.
nih.gov/pubmed/20817880.
24. Finnerty CC, Przkora R, Herndon DN, Jeschke MG (2009) Cytokine expression
profile over time in burned mice. Cytokine 45: 20–25. Available: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid = 2668870&tool = pmcentrez&
rendertype = abstract. Accessed 3 April 2013.
25. Agay D, Andriollo-Sanchez M, Claeyssen R, Touvard L, Denis J, et al. (2008)
Interleukin-6, TNF-alpha and interleukin-1 beta levels in blood and tissue in
severely burned rats. European cytokine network 19: 1–7. Available: http://
www.ncbi.nlm.nih.gov/pubmed/18299267. Accessed 3 April 2013.
26. Waitz R, Solomon SB, Petre EN, Trumble AE, Fasso` M, et al. (2012) Potent
induction of tumor immunity by combining tumor cryoablation with anti-
CTLA-4 therapy. Cancer research 72: 430–439. Available: http://www.ncbi.
nlm.nih.gov/pubmed/22108823. Accessed 3 April 2013.
27. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving
beyond current vaccines. Nature medicine 10: 909–915. Available: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid = 1435696&tool = pmcentrez&
rendertype = abstract. Accessed 3 April 2013.
28. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, et al. (2009) IL-17 can
promote tumor growth through an IL-6-Stat3 signaling pathway. The Journal of
experimental medicine 206: 1457–1464. Available: http://www.pubmedcentral.
nih.gov/articlerender.fcgi?artid = 2715087&tool = pmcentrez&rendertype =
abstract. Accessed 3 April 2013.
29. Park EJ, Lee JH, Yu G-Y, He G, Ali SR, et al. (2010) Dietary and genetic obesity
promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF
expression. Cell 140: 197–208. Available: http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid = 2836922&tool = pmcentrez&rendertype = abstract. Ac-
cessed 3 April 2013.
30. Albini A, Tosetti F, Benelli R, Noonan DM (2005) Tumor inflammatory
angiogenesis and its chemoprevention. Cancer research 65: 10637–10641.
Available: http://www.ncbi.nlm.nih.gov/pubmed/16322203. Accessed 3 April
2013.
31. Cuenca AG, Delano MJ, Kelly-Scumpia KM, Moreno C, Scumpia PO, et al.
(n.d.) A paradoxical role for myeloid-derived suppressor cells in sepsis and
trauma. Molecular medicine (Cambridge, Mass) 17: 281–292. Available: http://
www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3060988&tool =pmcentrez
&rendertype= abstract. Accessed 3 April 2013.
32. Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, et al. (2005) CD11b+/Gr-
1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors
of IL-1beta-secreting cells. Journal of immunology (Baltimore, Md: 1950) 175:
8200–8208. Available: http://www.ncbi.nlm.nih.gov/pubmed/16339559. Ac-
cessed 3 April 2013.
33. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2006)
Inflammation induces myeloid-derived suppressor cells that facilitate tumor
progression. Journal of immunology (Baltimore, Md: 1950) 176: 284–290.
Available: http://www.ncbi.nlm.nih.gov/pubmed/16365420. Accessed 3 April
2013.
34. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, et al. (2007) Reduced
inflammation in the tumor microenvironment delays the accumulation of
myeloid-derived suppressor cells and limits tumor progression. Cancer research
67: 10019–10026. Available: http://www.ncbi.nlm.nih.gov/pubmed/
17942936. Accessed 3 April 2013.
35. Waight JD, Hu Q, Miller A, Liu S, Abrams SI (2011) Tumor-derived G-CSF
facilitates neoplastic growth through a granulocytic myeloid-derived suppressor
cell-dependent mechanism. PloS one 6: e27690. Available: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid = 3218014&tool = pmcentrez&
rendertype = abstract. Accessed 3 April 2013.
36. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, et al. (1998)
Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by
tumor cells: role of interleukin-6 and macrophage colony-stimulating factor.
Blood 92: 4778–4791. Available: http://www.ncbi.nlm.nih.gov/pubmed/
9845545. Accessed 3 April 2013.
37. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, et al. (2004) High-dose
granulocyte-macrophage colony-stimulating factor-producing vaccines impair
the immune response through the recruitment of myeloid suppressor cells.
Cancer research 64: 6337–6343. Available: http://www.ncbi.nlm.nih.gov/
pubmed/15342423. Accessed 3 April 2013.
38. Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, et al. (1999)
Unopposed production of granulocyte-macrophage colony-stimulating factor by
tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell
maturation. Journal of immunology (Baltimore, Md: 1950) 162: 5728–5737.
Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid =
2228333&tool = pmcentrez&rendertype = abstract. Accessed 3 April 2013.
39. Fu YX, Watson G, Jimenez JJ, Wang Y, Lopez DM (1990) Expansion of
immunoregulatory macrophages by granulocyte-macrophage colony-stimulating
factor derived from a murine mammary tumor. Cancer research 50: 227–234.
Available: http://www.ncbi.nlm.nih.gov/pubmed/2136804. Accessed 3 April
2013.
40. Huang B, Lei Z, Zhao J, Gong W, Liu J, et al. (2007) CCL2/CCR2 pathway
mediates recruitment of myeloid suppressor cells to cancers. Cancer letters 252:
86–92. Available: http://www.ncbi.nlm.nih.gov/pubmed/17257744. Accessed
3 April 2013.
41. Den Brok MHMGM, Sutmuller RPM, Nierkens S, Bennink EJ, Toonen LWJ,
et al. (2006) Synergy between in situ cryoablation and TLR9 stimulation results
in a highly effective in vivo dendritic cell vaccine. Cancer research 66: 7285–
7292. Available: http://www.ncbi.nlm.nih.gov/pubmed/16849578. Accessed 3
April 2013.
42. Redondo P, Del Olmo J, Lo´pez-Diaz de Cerio A, Inoges S, Marquina M, et al.
(2007) Imiquimod enhances the systemic immunity attained by local cryosurgery
destruction of melanoma lesions. The Journal of investigative dermatology 127:
1673–1680. Available: http://www.ncbi.nlm.nih.gov/pubmed/17380112. Ac-
cessed 3 April 2013.
43. Habibi M, Kmieciak M, Graham L, Morales JK, Bear HD, et al. (2009)
Radiofrequency thermal ablation of breast tumors combined with intralesional
administration of IL-7 and IL-15 augments anti-tumor immune responses and
inhibits tumor development and metastasis. Breast cancer research and
treatment 114: 423–431. Available: http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid = 2649692&tool = pmcentrez&rendertype = abstract. Ac-
cessed 3 April 2013.
44. Castano AP, Mroz P, Wu MX, Hamblin MR (2008) Photodynamic therapy plus
low-dose cyclophosphamide generates antitumor immunity in a mouse model.
Proceedings of the National Academy of Sciences of the United States of
America 105: 5495–5500. Available: http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid = 2291083&tool = pmcentrez&rendertype = abstract. Ac-
cessed 3 April 2013.
45. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory
T cells in immunological tolerance to self and non-self. Nature immunology 6:
345–352. Available: http://www.ncbi.nlm.nih.gov/pubmed/15785760. Ac-
cessed 3 April 2013.
46. Gajewski TF (2007) Failure at the effector phase: immune barriers at the level of
the melanoma tumor microenvironment. Clinical cancer research: an official
journal of the American Association for Cancer Research 13: 5256–5261.
Available: http://www.ncbi.nlm.nih.gov/pubmed/17875753. Accessed 3 April
2013.
47. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, et al. (2005)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting
chemotherapy for the treatment of patients with refractory metastatic
melanoma. Journal of clinical oncology: official journal of the American Society
of Clinical Oncology 23: 2346–2357. Available: http://www.pubmedcentral.
nih.gov/articlerender.fcgi?artid = 1475951&tool = pmcentrez&rendertype =
abstract. Accessed 3 April 2013.
48. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, et al. (2008) Adoptive
cell therapy for patients with metastatic melanoma: evaluation of intensive
myeloablative chemoradiation preparative regimens. Journal of clinical
oncology: official journal of the American Society of Clinical Oncology 26:
5233–5239. Available: http://www.pubmedcentral.nih.gov/articlerender.
fcgi?artid = 2652090&tool = pmcentrez&rendertype = abstract. Accessed 3 April
2013.
49. Rosenberg SA, Dudley ME, Restifo NP (2008) Cancer immunotherapy. The
New England journal of medicine 359: 1072. Available: http://www.ncbi.nlm.
nih.gov/pubmed/18768956. Accessed 3 April 2013.
50. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, et al. (2009) Chemokine
expression in melanoma metastases associated with CD8+ T-cell recruitment.
Cancer research 69: 3077–3085. Available: http://www.ncbi.nlm.nih.gov/
pubmed/19293190. Accessed 3 April 2013.
51. Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, et al. (2007)
Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor
tropism of adoptively transferred T cells. Journal of immunology (Baltimore,
Md: 1950) 179: 3332–3341. Available: http://www.ncbi.nlm.nih.gov/pubmed/
17709550. Accessed 3 April 2013.
52. Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, et al. (2011) IL-6 trans-
signaling licenses mouse and human tumor microvascular gateways for
trafficking of cytotoxic T cells. The Journal of clinical investigation 121:
3846–3859. Available: http://www.pubmedcentral.nih.gov/articlerender.
fcgi?artid = 3195455&tool = pmcentrez&rendertype = abstract. Accessed 3 April
2013.
53. Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S (2012) Blockade of
myeloid-derived suppressor cells after induction of lymphopenia improves
adoptive T cell therapy in a murine model of melanoma. Journal of immunology
(Baltimore, Md: 1950) 189: 5147–5154. Available: http://www.ncbi.nlm.nih.
gov/pubmed/23100512. Accessed 11 June 2013.
Photothermal-Enhanced T Cell Therapy
PLOS ONE | www.plosone.org 13 July 2013 | Volume 8 | Issue 7 | e69073
